News & Events
Press Releases
Syncromune® Inc. Expands Scientific Advisory Board with Addition of Prominent Oncology Trailblazer James Armitage, M.D.
Eucure and Syncromune Establish Technology Transfer Agreement for YH002 (OX40 Antibody) and Multiple Other Clinical-Stage Antibodies
About Syncromune
Syncromune is a privately held, clinical-stage biopharmaceutical company dedicated to developing a completely in situ immunotherapy platform technology optimized for solid tumor cancers that achieves high clinical response rates with potentially curative efficacy. The company is currently developing SYNC-T, a novel platform technology that uses a drug/device combination therapy. The platform is designed to achieve personalized T cell education, enabling the immune system to recognize and attack cancer throughout the body. The first 2 candidates, SV-101 and SV-102 are currently in Phase 1 trials.
Upcoming Events
The following are meetings and conferences that the Syncromune team plans to attend. If you would like to meet with one of our team members, please email us at info@syncromune.com
January 8 – 11, 2024
The Westin St. Francis Hotel
San Francisco, CA
Meeting Information: https://www.jpmorgan.com/about-us/events-conferences/health-care-conference
April 5 – 10, 2024
San Diego Convention Center
San Diego, CA
AACR 2024 ANNUAL MEETING
Meeting Information: AACR Annual Meeting 2024 | Meetings | AACR
May 31 – June 4, 2024
McCormack Place
Chicago, IL
Past Events
SOCIETY FOR IMMUNOTHERAPY OF CANCER (SITC) ANNUAL MEETING
November 3 – 5, 2023
San Diego Convention Center
San Diego, CA